Fig. 2From: Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trialKaplan-Meier curves showing PFS results for a patients aged < 65 years, b patients aged ≥ 65 years, c patients with visceral metastases, d patients with high disease burden, and e patients with de novo disease. CI confidence interval, HR hazard ratio, NR not reached, PFS progression-free survivalBack to article page